FDA confirms that SciSparc’s study may proceedonly a month after application submission TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ...
MyChesCo on MSN1d
CluePoints Unveils Innovative Medical & Safety Review ApplicationCluePoints has announced the launch of its latest application, Medical & Safety Review (MSR), designed to revolutionize the ...
BUFFALO, NY / ACCESSWIRE / September 27, 2024 / POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical company, ...
In September 2024, the U.S. Food and Drug Administration (FDA) issued three guidance documents to support different clinical ...
Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...
Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating ...
New 56-week data from an interim analysis of the phase III ARCADIA long-term extension study will be presented, with nemolizumab demonstrating a ...
Based on Vizient’s analysis, the AHA using national hospitalization data projects that while caring for sicker patients, hospitals’ efforts to improve safety led to 200,000 Americans hospitalized ...
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
Italy: A recent analysis of the FDA Adverse Event Reporting System (FAERS) database has provided new insights into the safety ...
HEALWELL’s subsidiary, BioPharma Services, is expanding into late-stage patient trials through the integration of Canadian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback